STOCK TITAN
  1. Home
  2. Sec-filings
  3. PASW
  4. [6-K] Ping An Biomedical Co., Ltd. Current Report (Foreign Issuer)

Ping An Biomedical (Nasdaq: PASW) targets RMB 500m sales via health partnership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Ping An Biomedical Co., Ltd. reported that it has signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd., which will act as a channel development service provider. The partners share a goal of achieving cumulative sales of RMB 500 million within three years in the health and wellness services market.

Yuan Sheng Mei Yan will use its health management, wellness and government‑enterprise cooperation resources to expand channels and service scenarios, while Ping An Biomedical supplies biotechnology products and technical support. The company describes the cooperation as an important step in commercialization and channel development, aiming to broaden revenue sources and improve market penetration.

Positive

  • None.

Negative

  • None.
Sales target over cooperation term RMB 500 million Cumulative sales goal within three years under the strategic cooperation agreement
strategic cooperation agreement regulatory
"Ping An Biomedical announced that it has formally signed a strategic cooperation agreement"
A strategic cooperation agreement is a formal deal between two or more companies to work together on specific projects, share resources, or coordinate plans while remaining independent. For investors it signals potential cost savings, faster product development, access to new markets or shared risks—like neighbors pooling tools to finish a renovation sooner—so the agreement can influence future revenue, expenses and a company’s competitive position.
channel development service provider financial
"Under the agreement, Yuan Sheng Mei Yan will serve as a channel development service provider"
forward-looking statements regulatory
"This announcement contains "forward-looking" statements within the meaning of Section 27A"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
U.S. Private Securities Litigation Reform Act of 1995 regulatory
"made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995"
A federal law that changed the rules for suing companies over securities claims by making it harder to bring class-action lawsuits and by protecting certain forward-looking statements. Think of it as a rulebook that raises the bar for plaintiffs to show clear evidence of wrongdoing and gives companies limited shelter for predictions, which matters to investors because it can reduce litigation risk, legal costs, and volatility tied to lawsuit headlines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did Ping An Biomedical (PASW) announce in its July 2026 Form 6-K?
Ping An Biomedical (PASW) disclosed a signed strategic cooperation agreement with Yuan Sheng Mei Yan. The partner will act as a channel development service provider, targeting RMB 500 million cumulative sales over three years in China’s broader health and wellness services market.

What is the RMB 500 million sales target mentioned by Ping An Biomedical (PASW)?
The agreement sets a shared goal of achieving RMB 500 million in cumulative sales within three years. This target relates to products and services promoted through Yuan Sheng Mei Yan’s health management, wellness, and scenario-based service network as part of the cooperation.

What role will Yuan Sheng Mei Yan play for Ping An Biomedical (PASW)?
Yuan Sheng Mei Yan will serve as a channel development service provider for Ping An Biomedical (PASW). It leverages health management expertise, high-end customer operations, and government-enterprise partnerships to expand product channels, support market outreach, and implement terminal health service scenarios.

How does the cooperation support Ping An Biomedical (PASW)’s commercialization strategy?
Ping An Biomedical (PASW) states the deal is an important step in advancing commercialization and channel development. By pairing its biotechnology products with Yuan Sheng Mei Yan’s service scenarios, it expects faster transformation from R&D to consumer applications and broader revenue sources.

Which markets and service scenarios are targeted in Ping An Biomedical (PASW)’s partnership?
The cooperation focuses on personalized health management, cell-level wellness, and technology-driven anti-aging services. Yuan Sheng Mei Yan’s full-scenario network across prevention, care, and intervention is expected to help Ping An Biomedical (PASW) place related products into more health and wellness application settings.

What forward-looking information did Ping An Biomedical (PASW) include with this cooperation?
The company included forward-looking statements about objectives, plans, and strategies, including the RMB 500 million sales goal. It cautions that various risks and uncertainties could cause actual results to differ materially from these expectations, citing factors in its SEC filings.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2026

 

Commission File Number No. 001-42155

 

Ping An Biomedical Co., Ltd.

(Registrant’s Name)

 

22/F, China United Plaza

1002-1008, Tai Nan West Street

Cheung Sha Wan

Kowloon, Hong Kong

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

 

 

 

 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

 

On July 22, 2026, Ping An Biomedical Co., Ltd. (the “Company”) issued a press release announcing the Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years.

 

A copy of the press release is furnished as Exhibit 99.1 to this Form 6-K.

 

Exhibits

 

Exhibit No.   Description of Exhibit
99.1   Press Release, dated July 22, 2026

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  PING AN BIOMEDICAL CO., LTD.
     
Date: July 22, 2026 By: /s/ Pijun Liu
  Name:  Pijun Liu
  Title: Chairman of the Board of Directors

 

2

 

 

Exhibit 99.1

 

Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years

 

Hong Kong, July 22, 2026 — Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (hereinafter referred to as “Ping An Biomedical”) announced that it has formally signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd. (hereinafter referred to as “Yuan Sheng Mei Yan”). Under the agreement, Yuan Sheng Mei Yan will serve as a channel development service provider for Ping An Biomedical. The two parties will engage in deep cooperation in the broader health and wellness services market, with a shared goal of achieving cumulative sales of RMB 500 million within three years.

 

Under the cooperation arrangement, Yuan Sheng Mei Yan will leverage its comprehensive capabilities in health management, wellness services, and high-end customer operations to assist Ping An Biomedical in expanding product channels, promoting market outreach, and facilitating terminal service implementation. Ping An Biomedical, in turn, will draw on its strengths in biotechnology, health products, and research and development to provide product supply and technical support, helping both parties build a synergistic system spanning products, services, and market conversion.

 

Ping An Biomedical stated that this collaboration represents an important step in advancing the company’s commercialization efforts and channel development. By introducing a partner with health service scenarios, direct customer access capabilities, and platform operation capabilities, the company expects to accelerate the transformation of products from the R&D stage to consumer and service applications, further broaden revenue sources, and improve market penetration.

 

As an innovative enterprise focused on the integration of biotechnology and health services, Yuan Sheng Mei Yan has already established a relatively complete service framework in areas such as personalized health management, cell-level wellness services, and technology-driven anti-aging health services. Centered on the core logic of “technology development — health services — scenario implementation,” the company has built a strong user service loop through health assessments, customized solutions, dynamic tracking, and offline service delivery, which is expected to help Ping An Biomedical improve customer conversion efficiency and user stickiness during market expansion.

 

In terms of channel expansion and scenario implementation, Yuan Sheng Mei Yan also has strong capabilities in government-enterprise cooperation and service network development. The company has established partnerships with the government of Huairou District in Beijing, relevant departments in Shenyang, and others, participating in the construction of regional health service systems. Leveraging local policy support and industrial resources, it is advancing the development of health service bases and testing centers. Such local cooperation experience is expected to support Ping An Biomedical’s future localized expansion in different regional markets, improving service accessibility and regional penetration.

 

Furthermore, through cross-sector cooperation with medical institutions, wellness organizations, and insurance providers, Yuan Sheng Mei Yan is gradually building a full-scenario health service network covering “prevention, care, and intervention.” This multi-tiered service network is expected to help Ping An Biomedical’s related products enter a wider range of application scenarios more quickly, while combining extended services such as health management and insurance to enhance product value and commercialization efficiency.

 

 

 

 

The key to this cooperation lies in the complementary relationship between Ping An Biomedical’s product supply side and Yuan Sheng Mei Yan’s service channel side. Ping An Biomedical provides biotechnology products and technical support, while Yuan Sheng Mei Yan leverages its professional team, channel capabilities, government-enterprise resources, and scenario-based service network to support market education, customer conversion, and service implementation, thereby creating a business loop from technology and products to end-user consumption. As China’s health and wellness industry continues to move toward greater precision, technological sophistication, and service orientation, cooperation models that combine technical capabilities with end-scenario integration are becoming an increasingly important path for growth across the industry chain.

 

About Ping An Biomedical Co., Ltd

 

Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.

 

Safe Harbor and Informational Statement

 

This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, our ability to timely and accurately respond to changes in fashion trends and consumer preferences; management of customer concentration risk; reliance on third parties for supplies of raw materials, manufacturing services and transport infrastructure; changes in government policy in China; China’s overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in Ping An Biomedical Co., Ltd’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of the issuance, and Ping An Biomedical Co., Ltd does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

For more information, please contact:

 

Ping An Biomedical Co., Ltd.

Email: corpsec@pingan365.vip

 

Celestia Investor Relations

Email: investors@celestiair.com

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases